Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Solasia Grants Japan Rights for Darinaparsin to Nippon Kayaku, Ends Deal with Meiji
October 27, 2021
- Daiichi Sankyo, AstraZeneca to Launch PIII of DS-1062/Keytruda Combo
October 27, 2021
- Sun Pharma Japan to Boost Sales Force, Development to Achieve 1.5-Fold Sales Growth by 2025
October 27, 2021
- Oncolys’ Oral COVID-19 Drug Effective in Hamster Model
October 27, 2021
- MSD Seeks Japan Approval for 15-Valent Pneumococcal Vaccine
October 27, 2021
- Extension of Use Patent Term for Remitch Affirmed: Toray
October 27, 2021
- Choseido Revamps Management, Sacks President Harada over GMP Violations
October 26, 2021
- Sanofi, Nichi-Iko to Dissolve Joint Venture at Year-End
October 26, 2021
- KM Biologics Eyes COVID-19 Booster Filing as Early as Spring, Trial Start Slated by Year-End
October 26, 2021
- Keytruda Filed for Neoadjuvant/Adjuvant Therapy for TNBC in Japan
October 26, 2021
- Rakuten Medical, Karkinos Tie Up in Novel Cancer Care in India
October 25, 2021
- Chugai’s 9-Month Sales Up 17.5% on Ronapreve, 42.8 Billion Yen Booked in Govt Purchase
October 25, 2021
- KM Biologics’ COVID-19 Jab Enters Japan PII/III Study
October 25, 2021
- MSD Seeks Cervical Cancer Nod for Keytruda in Japan
October 25, 2021
- Kaken’s Approval-Pending Eschar Remover Hits Goal in PIII Study
October 22, 2021
- Shionogi Launches Japan PII/III for COVID-19 Vaccine
October 22, 2021
- Daiichi Sankyo Eyes Booster Dose Trial Launch in January
October 22, 2021
- Mundipharma Japan Set to Cut into High Production Costs, Boost Profitability to Lure Investments: President
October 22, 2021
- Taiwan OKs Opdivo-Chemo Combo for Gastric Cancer: Ono
October 21, 2021
- Meiji Pharma Rolls Out ATLL Drug Hiyasta in Japan
October 21, 2021
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…